Metabolites in safety testing: MIST for the clinical pharmacologist

Clinical Pharmacology and Therapeutics

Volumn 87, Issue 3, 2010, Pages 345-350

  Frederick, C B ^a   Obach, R S ^b  

^a MERCK RESEARCH LABORATORIES   (United States)

^b PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BENZODIAZEPINE DERIVATIVE; CARBAMAZEPINE; DRUG METABOLITE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; N ACETYL 1,4 BENZOQUINONE IMINE; NOMIFENSINE; OPIATE DERIVATIVE; PARACETAMOL; PHENYTOIN; SELECTIVE ESTROGEN RECEPTOR MODULATOR; TERFENADINE;

CHEMICAL REACTION; DRUG METABOLISM; DRUG RESEARCH; DRUG SAFETY; DRUG STRUCTURE; FOOD AND DRUG ADMINISTRATION; HUMAN; ISOTOPE LABELING; LIPOPHILICITY; LIVER TOXICITY; MEDICAL SOCIETY; NONHUMAN; PLASMA PROTEIN BINDING; PRIORITY JOURNAL; REVIEW; TOBACCO;

ANIMALS; CLINICAL TRIALS AS TOPIC; DRUG APPROVAL; HUMANS; PHARMACEUTICAL PREPARATIONS; PHARMACOLOGY, CLINICAL; UNITED STATES;

EID: 77149125562     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/clpt.2009.283     Document Type: Review

References (30)

1. US Food and Drug administration. Guidance for Industry: Safety Testing of Drug Metabolites (2008).
2. International conference on harmonisation. Non-Clinical Safety Studies for the conduct of human Clinical Trials for Pharmaceuticals. Ich Guidance M3(R2) (2009).
3. Baillie, T.a. et al. Drug metabolites in safety testing. Toxicol. Appl. Pharmacol. 182,188-196(2002).
4. Hastings, K.L., El-Hage, J., Jacobs, A., Leighton, J., Morse, D. & Osterberg, R.E. Drug metabolites in safety testing. Toxicol. Appl. Pharmacol. 190,91-92; reply, 93 (2003).
5. Baillie,T.A. et al. Response to Letter to the Editor. Toxicol. Appl. Pharmacol. 190, 93-94(2003).
6. Food and Drug administration. Guidance for Industry: Safety Testing of Drug Metabolites (Draft Guidance) (2005)
7. Prueksaritanont,T., Lin, J.H.&Baillie,T.A. Complicating factors in safety testing of drug metabolites: kinetic diferences between generated and preformed metabolites. Toxicol. Appl. Pharmacol. 217,143-152 (2006).
8. Smith, Da. & Obach, R.S. Seeing through the mist: abundance versus percentage. commentary on metabolites in safety testing. Drug Metab. Dispos. 33,1409-1417 (2005).
9. Smith, Da. & Obach, R.S. Metabolites and safety: What are the concerns, and how should we address them? Chem. Res. Toxicol. 19,1570-1579 (2006).
10. Atrakchi, A.H. Interpretation and considerations on the safety evaluation of human drug metabolites. Chem. Res. Toxicol. 22,1217-1220 (2009).
11. Baillie, T.A. approaches to the assessment of stable and chemically reactive drug metabolites in early Clinical trials. Chem. Res. Toxicol. 22, 263-266 (2009).
12. Leclercq, L, Cuyckens, F., Mannens, G.S., de Vries, R., Timmerman, P. & Evans, D.C. Which human metabolites havewe MIST? Retrospective analysis, practical aspects, and perspectives for metabolite identification and quantification in pharmaceutical development. Chem. Res. Toxicol. 22, 280-293 (2009).
13. Bailey, M.J. & Dickinson, R.G. Acyl glucuronide reactivity in perspective: biological consequences. Chem. Biol. Interact. 145,117-137 (2003).
14. Shipkova, M., armstrong, V.W, Oellerich, M. & Wieland, E. Acyl glucuronide drug metabolites: toxicological and analytical implications. Ther. Drug Monit. 25,1-16(2003).
15. Park, B.K., Pirmohamed, M.&Kitteringham, N.R. Role of drug disposition in drug hypersensitivity: a chemical, molecular, and Clinical perspective. Chem. Res. Toxicol. 11,969-988 (1998).
16. Guengerich, F.P.&MacDonald,J.S. Applying mechanisms of chemical toxicity to predict drug safety. Chem. Res. Toxicol. 20,344-369 (2007)
17. Kalgutkar, A.S., Obach, R.S. & Maurer, T.S. Mechanism-based inactivation of cytochrome P450 enzymes: chemical mechanisms, structure-activity relationships and relationship to Clinical drug-drug interactions and idiosyncratic adverse drug reactions. Curr. Drug Metab. 8,407-447 (2007).
18. European Medicines agency. Non-Clinical Guideline on Drug-Induced Hepatotoxicity (Draft Guideline) (2008).
19. Slattery, J.T., Wilson, J.M., Kalhorn,T.F. & Nelson, S.D. Dose-dependent pharmacokinetics of acetaminophen: evidence of glutathione depletion in humans. Clin. Pharmacol. Ther. 41,413-418 (1987).
20. Kalgutkar, a.S. et al. A comprehensive listing of bioactivation pathways of organic functional groups. Curr. Drug Metab. 6; 161-225 (2005).
21. Bateman, K.P. et al. MSE with mass defect fltering for in vitro and in vivo metabolite identification. Rapid Commun. Mass Spectrom. 21, 1485-1496(2007)
22. Zhang, h., Zhu, M., Ray, K.L., Ma, L & Zhang, D. Mass defect profles of biological matrices and the general applicability of mass defect fltering for metabolite detection. Rapid Commun. Mass Spectrom. 22,2082-2088 (2008).
23. Dalvie, D. et al. assessment of three human in vitro systems in the generation of major human excretory and circulating metabolites. Chem. Res. Toxicol. 22,357-368 (2009).
24. Anderson, S., Lufer-atlas, D. & Knadler, M.P. Predicting circulating human metabolites: how good are we? Chem. Res. Toxicol. 22,243-256 (2009).
25. Zhang, D. et al. Lc-MS/MS-based approach for obtaining exposure estimates of metabolites in early Clinical trials using radioactive metabolites as reference standards. Drug. Metab. Lett. 1, 293-298 (2007).
26. Vishwanathan, K. et al. Obtaining exposures of metabolites in preClinical species through plasma pooling and quantitative NMR: addressing metabolites in safety testing (MIST) guidance without using radiolabeled compounds and chemically synthesized metabolite standards. Chem. Res. Toxicol. 22,311-322 (2009).
27. Walker, D. et al. a holistic strategy for characterizing the safety of metabolites through drug discovery and development. Chem Res. Toxicol. 22,1653-1662 (2009).
28. Rofey, S.J., Obach, R.S., Gedge, J.I. & Smith, DA. What is the objective of the mass balance study? a retrospective analysis of data in animal and human excretion studies employing radiolabeled drugs. Drug Metab. Rev. 39, 17-43(2007).
29. Davis-Bruno, K.L. & Atrakchi, A. A regulatory perspective on issues and approaches in characterizing human metabolites. Chem. Res. Toxicol. 19, 1561-1563(2006).
30. Powley, M.W, Frederick, C.B., Sistare, F.D. & DeGeorge, J.J. Safety assessment of drug metabolites: implications of regulatory guidance and potential application of genetically engineered mouse models that express human P450s. Chem. Res. Toxicol. 22,257-262 (2009).